Unknown

Dataset Information

0

First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial.


ABSTRACT: The purpose of our study was to compare progression-free survival and quality of life (QOL) after cisplatin-gemcitabine (CG) or epirubicin-gemcitabine (EG) in chemotherapy-naive patients with unresectable non-small-cell lung cancer. Patients (n=240) were randomised to receive gemcitabine 1125 mg x m(-2) (days 1 and 8) plus either cisplatin 80 mg x m(-2) (day 2) or epirubicin 100 mg x m(-2) (day 1) every 3 weeks for a maximum of five cycles. Eligible patients had normal organ functions and Eastern Cooperative Oncology Group performance status

SUBMITTER: Wachters FM 

PROVIDER: S-EPMC2394313 | BioStudies | 2003-01-01

SECONDARY ACCESSION(S): 10.1038/sj.bjc.6601283

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5597318 | BioStudies
2019-01-01 | S-EPMC6540535 | BioStudies
2019-01-01 | S-EPMC6513743 | BioStudies
2009-01-01 | S-EPMC2792952 | BioStudies
2019-01-01 | S-EPMC6421214 | BioStudies
2015-01-01 | S-EPMC4424571 | BioStudies
1000-01-01 | S-EPMC4298376 | BioStudies
2012-01-01 | S-EPMC3397785 | BioStudies
2016-01-01 | S-EPMC4984909 | BioStudies
2020-01-01 | S-EPMC7106641 | BioStudies